Document › Details

Uniqure N.V.. (4/29/19). "Press Release: Uniqure Announces First Quarter 2019 Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam.

	Organisation	Uniqure N.V. (Nasdaq: QURE)
	Group	Uniqure (Group)
	Organisation 2	FDA (US Food and Drug Administration)
	Group	United States (govt)
	Product	AMT-061 (hemophilia B gene therapy, Uniqure)
	Product 2	AMT-130 (Huntington’s disease gene therapy, Uniqure)
	Person	Kapusta, Matthew (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew Orthopaedics)
	Person 2	Cantor, Maria E. (Uniqure 201606– SVP IR + Communications before Ariad Pharmaceuticals + Genzyme)

Original document
accessed by [iito] on 2019-05-15

Record changed: 2019-05-23

More documents for Uniqure (Group)

[1] Uniqure N.V.. (5/10/19). "Press Release: Uniqure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B". Lexington, MA & Amsterdam....
[2] Uniqure N.V.. (5/1/19). "Press Release: Uniqure to Participate in Multiple Upcoming Industry Conferences". Lexington, MA & Amsterdam....
[3] Uniqure N.V.. (4/8/19). "Press Release: Uniqure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease". Lexington, MA & Amsterdam....
[4] Uniqure N.V.. (3/29/19). "Press Release: Uniqure to Participate in Multiple Upcoming Industry Conferences". Lexington, MA & Amsterdam....
[5] Uniqure N.V.. (3/1/19). "Press Release: Uniqure to Participate in Multiple Upcoming Industry Conferences". Lexington, MA & Amsterdam....
[6] Uniqure N.V.. (2/28/19). "Press Release: Uniqure Announces 2018 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....
[7] Uniqure N.V.. (2/8/19). "Press Release: Uniqure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B". Lexington, MA & Amsterdam....
[8] Uniqure N.V.. (1/22/19). "Press Release: Uniqure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease". Lexington, MA & Amsterdam....
[9] Uniqure N.V.. (8/30/18). "Press Release: Uniqure to Participate at Multiple Upcoming Conferences". Lexington, MA & Amsterdam....
[10] Uniqure N.V.. (8/23/18). "Press Release: Uniqure Announces First Patient Treated in Dose-confirmation Study of AMT-061 in Patients with Hemophilia B". Lexington, MA & Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]